(2RS)-FPMPA

CAS No. 135295-27-1

(2RS)-FPMPA( —— )

Catalog No. M35992 CAS No. 135295-27-1

(2RS)-FPMPA(FPMPA) has antiviral activity with an IC50 value of 1.85 μM measured in human MT12 cells infected with SHIV (DH4R).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 610 In Stock
10MG 867 In Stock
25MG 1302 In Stock
50MG 1721 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    (2RS)-FPMPA
  • Note
    Research use only, not for human use.
  • Brief Description
    (2RS)-FPMPA(FPMPA) has antiviral activity with an IC50 value of 1.85 μM measured in human MT12 cells infected with SHIV (DH4R).
  • Description
    (2RS)-FPMPA can be used for synthesis of antiretroviral agents against HIV-1 and HIV-2.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV Protease
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    135295-27-1
  • Formula Weight
    305.2
  • Molecular Formula
    C9H13FN5O4P
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(C(OCP(=O)(O)O)CF)N1C=2C(N=C1)=C(N)N=CN2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Balzarini J, et al. 9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4961-5. ?
molnova catalog
related products
  • TAK-779

    TAK-779 is a potent, specific, nonpeptide CCR5 antagonist with Kd of 0.45 nM.

  • KM-023

    KM-023 is a new second-generation non-nucleoside reverse transcriptase inhibitor for the study of human immunodeficiency virus (HIV) type 1 infection.

  • PF-3450074

    PF-3450074 (PF74) is a small molecule HIV capsid protein, destabilized the viral capsid in vitro; acts at an early stage of HIV-1 infection and inhibits reverse transcription in target cells.